Supporting Information

A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

Author List: Scott C. Jeffrey,[*] Patrick J. Burke,[†] Robert P. Lyon,[†] David W. Meyer,[†] Django Sussman,[†] Martha Anderson,[†] Chris I. Lieske,[†] Joshua H. Hunter,[†] Jamie B. Miyamoto,[†] Nicole D. Nicholas,[†] Nicole M. Okeley,[†] Russell J. Sanderson,[†] Ivan Stone,[†] Weiping Zeng,[†] Stephen J. Gregson,[‡] Luke Masterson,[‡] Arnaud C. Tiberghien,[‡] Philip W. Howard,[‡] David E. Thurston,[§] Che-Leung Law,[†] Peter D. Senter [†]

[†]Department of Research & Translational Medicine, Seattle Genetics, Inc., Bothell, WA 98021.
[‡]Spirogen Ltd., QMB Innovation Centre, 42 New Road, London E1 2AX, United Kingdom.
[§]Department of Pharmacy, Institute of Pharmaceutical Sciences, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH.

Index:



Figure S1. Analytic assessment of hinge cysteine conjugates. A, Size exclusion chromatography of h1F6-PBD(4) and (B) h1F6-PBD(2). C, Hydrophobic interaction chromatography of h1F6-PBD(2) showed 51% of ADC mixture was unconjugated h1F6.



Figure S2. Ex vivo rat plasma stability of h1gG_{239C}-PBD. Resin-captured ADC from rat plasma was assessed for heavy chain drug-loading by PLRP and showed no significant loss of drug over 6 days.